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Alveolar macrophages abundantly express PPAR-γ, with both natural and synthetic agonists maintaining the cell in a quiescent
state hyporesponsive to antigen stimulation. Conversely, agonists upregulate expression and function of the cell-surface receptor
CD36, which mediates phagocytosis of lipids, apoptotic neutrophils, and other unopsonized materials. These eﬀects led us to in-
vestigate the actions of PPAR-γ agonists on the Fcγ receptor, which mediates phagocytosis of particles opsonized by binding of
immunoglobulin G antibodies. We found that troglitazone, rosiglitazone, and 15-deoxy-Δ
12,14-prostaglandin J2 increase the ability
of alveolar, but not peritoneal, macrophages to carry out phagocytosis mediated by the Fcγ receptor. Receptor expression was not
altered but activation of the downstream signaling proteins Syk, ERK-1, and ERK-2 was observed. Although it was previously
known that PPAR-γ ligands stimulate phagocytosis of unopsonized materials, this is the ﬁrst demonstration that they stimulate
phagocytosis of opsonized materials as well.
Copyright © 2007 David M. Aronoﬀ et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Phagocytosis—engulfment of invading pathogens, particu-
lates, and dying cells—is a crucial homeostatic mechanism
in multicellular organisms. Most mammalian phagocytosis
is carried out by macrophages or neutrophils. This process
begins with adhesion of the material to be phagocytosed to
a receptor on the macrophage or neutrophil surface. The re-
ceptor then triggers intracellular signals that lead to a zipper-
like infolding of the cell membrane, engulﬁng the receptor
and that which is bound to it. Further signals cause transport
of the resulting endosome to the lysosome, where enzymes
are available to digest commonly phagocytosed materials.
Both oposonin-dependent and-independent classes of
cell-surface receptors mediate phagocytosis. Among the for-
mer are the Fc receptors that recognize the Fc portion of
an immunoglobulin bound through its antigen-recognition
site to the target particle or organism [1]. The most im-
portant of these is the Fcγ receptor for immunoglobulin G
(IgG), but Fcα receptors and Fcε receptors (for the Fc por-
tions of immunoglobulin A and immunoglobulin E, resp.)
also exist. Complement receptors also recognize opsonized
particles that are bound with complement proteins [2]. The
broad class of opsonin-independent receptors involved in
immune surveillance and phagocytosis includes the Toll-like
and scavenger receptors that recognize apoptotic cells, mi-
crobial components, and other unopsonized materials [3, 4].
The nuclear receptor, peroxisome proliferator-activated
receptor-γ (PPAR-γ), is expressed in a variety of cells of
the immune system, including macrophages, neutrophils,
eosinophils, lymphocytes, and mast cells. This receptor is
expressed abundantly in alveolar macrophages (AMs) [5–7]
but atmuch lowerlevels in resident macrophages ofthe bone
marrow and peritoneum [6, 7]. In peritoneal macrophages2 PPAR Research
(PMs) that have been elicited by activating agents such as
thioglycolate, however, PPAR-γ is upregulated signiﬁcantly
[7].
Many aspects of AM function have been found to be
modulated by both natural and synthetic PPAR-γ ligands
[8]. For example, PPAR-γ ligands inhibit the ability of var-
ious stimuli to induce production of proinﬂammatory medi-
ators, including tumor necrosis factor-α and interleukin-12,
expression of inducible nitric oxide synthase, and the pro-
duction of reactive oxygen species [5, 6]. Conversely, activa-
tion of PPAR-γ in AMs has been shown to upregulate phago-
cytosis of apoptotic neutrophils through increased expres-
sion of the CD36 surface receptor [5]. PPAR-γ ligands have
also been shown to increase CD36-mediated phagocytosis of
senescent neutrophils and ﬂuorescent-labeled latex beads by
pancreatic stellate cells [9].
In light of these results, we hypothesized that activation
of PPAR-γ could regulate Fcγ receptor-mediated phagocyto-
sis. We therefore performed experiments in both AMs and
PMs using IgG-opsonized phagocytic targets and ligands for
PPAR-γ.
2. MATERIALS AND METHODS
2.1. Animals
Pathogen-free 129/SvEv mice (The Jackson Laboratory, Bar
Harbor, Me, USA) and 125–150gm female Wistar rats
(Charles River Laboratories, Portage, Mish, USA) were uti-
lized. Animals were treated according to National Institutes
of Health guidelines for the use of experimental animals with
the approval of the University of Michigan Committee on
Use and Care of Animals.
2.2. Reagents
O-phenylenediamine dihydrochloride, 3-(4,5-dimethyl-
thiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT),
and sodium dodecyl sulfate were obtained from Sigma-
Aldrich (St. Louis, Mo, USA). Uniform, superparamagnetic,
2.8 micron polystyrene beads covalently coated with IgG
were purchased from Dynal-Invitrogen (Carlsbad, Calif,
USA). Troglitazone, rosiglitazone, and 15-deoxy-Δ12,14-
prostaglandin J2(15d-PGJ2) were obtained from Cayman
Chemical (Ann Arbor, Mich, USA). These compounds
were dissolved in DMSO to a stock concentration of
10mM and stored at −80◦C prior to use. RPMI-1640 and
penicillin/streptomycin/amphotericin B solutions were
purchased from Gibco-Invitrogen (Carlsbad, Calif, USA).
Tryptic soy broth was supplied by Difco (Detroit, Mich,
USA). Klebsiella pneumoniae 43816, serotype 2, wasobtained
from the American Type Culture Collection (Rockville, Md,
USA); aliquots were grown until mid-log phase in TSB at
37◦C under 5% CO2 atmosphere. The concentration of
bacteria in culture was determined spectrophotometrically
at 600nm [10]. Required dilutions of all compounds were
prepared immediately before use and equivalent quantities
of vehicle were added to the appropriate controls.
2.3. Cellisolationandculture
Resident AMs from mice and rats were obtained via ex vivo
lung lavage as previously described [11] and resuspended
in RPMI to a ﬁnal concentration of 2 × 106 cells/mL. Res-
ident peritoneal macrophages (PMs) from mice and rats
were harvested by lavage as previously published [12]. Cells
were allowed to adhere to tissue-culture-treated slides/plates
for 1 hour at 37◦Ci na5 %C O 2 atmosphere, followed
by two washings with warm RPMI to remove nonadher-
ent cells. Prior to use, macrophages were cultured overnight
in RPMI containing 10% fetal bovine serum and 1% peni-
cillin/streptomycin/amphotericin B. On the following day,
cells were washed again with a warm medium to remove
nonadherent cells.
2.4. Microcolorimetricerythrocytephagocytosisassay
Macrophage phagocytosis of IgG-opsonized sheep red blood
cells (SRBCs) was assessed as previously described [13, 14].
Brieﬂy, cells were plated and cultured overnight in 96-well
culture-treated dishes (Becton, Dickinson, Franklin Lakes,
NJ, USA) at a density of 2×105 cells/well and in the presence
of PPAR-γ ligands or vehicle controls. SRBCs (ICN, Costa
Mesa, Calif, USA) were opsonized with a subagglutinating
concentration of polyclonal rabbit anti-SRBC IgG (Organon
Teknika-Cappel, Durham, NC, USA). Macrophages were
then washed twice with warm RPMI and preincubated for
45minuteswithcytochalasinD(5μg/mL)orvehicle.Follow-
ing preincubation, opsonized SRBCs were added at a ratio of
50 : 1 (SRBC : macrophage) and cultures were incubated for
an additional 90 minutes at 37◦C. Wells were then washed
three times with phosphate buﬀered saline to remove non-
ingested erythrocytes and 100μL of 0.3% sodium dodecyl
sulfate in phosphate buﬀered saline was added to each well
for10minutes.Astandardcurvewasderivedbyaddingserial
dilutions of known numbers of SRBCs to separate wells fol-
lowed by addition of sodium dodecyl sulfate solution. Lastly,
100μLofO-phenylenediaminedihydrochloridesolutionwas
added to each well as a chromogen. Following a 30-minute
incubationinthedarkat22◦C,theabsorbance(A)at450nm
was evaluated with an automated reader (VersaMAX, Molec-
ular Devices, Sunnyvale, Calif, USA). The number of SRBCs
per well was derived from A450 data using the standard curve
preparedasdescribed.Thephagocyticindex(PI)wasdeﬁned
as the number of SRBCs in an experimental well (ingested +
adhered SRBCs) minus the mean number of SRBCs in wells
treated with the phagocytosis inhibitor cytochalasin D (ad-
hered SRBCs) and was expressed as the percentage of the
control. Independent experiments were performed in septu-
plet.
2.5. PhagocytosisofIgG-opsonizedbeads
Phagocytosis of IgG-opsonized beads (IgG-beads) was quan-
tiﬁed via light microscopy. Macrophages were cultured on 8-
chamber glass slides before the challenge with IgG-beads at
ar a t i oo f4 0b e a d s / c e l l .P P A R - γ ligands or vehicle controls
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in Section 3 and/or ﬁgure legends. Experiments were termi-
nated and uningested IgG-beads were removed by aspirating
supernatants and washing slides three times with cold phos-
phate buﬀered saline. Slides were subsequently stained with
a modiﬁed Wright-Giemsa stain and examined under light
microscopy. The PI was determined from 200 cells per well
by multiplying the percentage of macrophages containing at
least 1 IgG-bead by the mean number of IgG-beads per posi-
tive cell [13, 15]. The ability to distinguish intracellular from
surface-associated IgG-beads was veriﬁed by comparing the
PI of untreated cells with that of cells exposed for 30 minutes
to the phagocytosis inhibitor cytochalasin D (5μg/mL) [16].
A minimum of 4 replicate wells per condition was studied in
each experiment.
2.6. Phagocytosisoflive,serum-opsonizedbacteria
Once the Gram-negative pathogen K. pneumoniae has been
opsonized with immune serum, it is subject to phagocytosis
by alveolar macrophages via the Fcγ class of receptors [17].
We assessed phagocytosis of K. pneumoniae based on a pro-
tocol for bacterial killing that we have previously published
[18]. Brieﬂy, rat AMs at a concentration of 2 × 106/mL, pre-
pared as described, were seeded in a 96-well tissue culture
dish and exposed to PPAR-γ ligands or vehicle controls for
18 hours. The next day, K. pneumoniae were opsonized with
3% anti-K. pneumoniae rat-derived immune serum, as pre-
viously described [16]. Macrophages were then infected with
a 0.1-mL suspension of opsonized K. pneumoniae (1 × 107
colony-forming units/mL; multiplicity of infection, 50 : 1)
and incubated for 30 minutes to allow phagocytosis to oc-
cur. Cells were then washed three times with 100μL of phos-
phate buﬀered saline to remove noningested bacteria, after
which the macrophages were lyzed with 100μLo fT S Bc o n -
taining 0.5% saponin (which did not lyze the bacteria). Cul-
t u r e sw e r ei n c u b a t e df o r2h o u r sa t3 7 ◦C to amplify bacte-
rial growth prior to the addition of the tetrazolium salt MTT
(5mg/mL in phosphate buﬀered saline). Plates were held for
30 minutes at 37◦C, after which the purple formazan salt was
solubilizedwithasolutionofisopropanol/0.1NHCLand1%
Triton X-100 [19]. The intensity of the absorbance at 595nm
was directly proportional to the number of intracellular bac-
teria associated with the macrophages [19]. Results are ex-
pressed as a percent of the untreated cells.
2.7. Immunoblotanalysis
Western blots were performed as previously described [20].
Brieﬂy, the whole cell protein extracts were obtained by lyz-
ing freshly harvested AMs in a buﬀer [50 mM Tris-HCl (pH
7.4), 25mM KCl, 5mM MgCl2, 0.2% Nonidet P-40] sup-
plemented with protease and phosphatase inhibitors (Roche
Diagnostics, Mannheim, Germany). Protein samples (40μg)
were resolved on 10% Tris-HCl polyacrylamide gels and sub-
sequently transferred to nitrocellulose membranes. Mem-
branes were probed with commercially available rabbit poly-
clonal antibodies against phospho-spleen tyrosine kinase
(phospho-Syk; Tyr525/526; Cell Signaling Technology, Dan-
vers, Mass, USA; 1 : 500), total Syk (Santa Cruz Biotech-
nology, Inc., Calif, USA; 1 : 800), total p42/44 (ERK-1/2;
Cell Signaling Technology; 1 : 1000), or with mouse mono-
clonal antibodies against β-actin (Sigma-Aldrich; 1 : 10000)
or phospho-p42/44 (Tyr204/Thr202; Cell Signaling Tech-
nology; 1 : 1000) followed in either case by horseradish
peroxidase-conjugated antirabbit or antimouse, respectively,
secondary antibodies, and ECL chemiluminescence detec-
tion reagents (Amersham Biosciences, Piscataway, NJ, USA).
For experiments involving activation of the Fcγ receptor,
AMs were treated for 7 minutes with IgG-SRBCs at a ratio of
33 SRBC per macrophage [21]. Band density from Western
blots was determined using Adobe Photoshop 6.0 (Adobe,
San Jose, Calif, USA).
2.8. RT-PCRofFcγ receptorsI,IIB,andIII
T h em R N Ae x p r e s s i o no fF c γ receptors I, IIB, and III was de-
termined in macrophages treated for 16 hours with troglita-
zone (5μM) or with DMSO vehicle. RNA from cultured cells
wasisolatedusingtheRNeasyMiniKit(Qiagen,Hilden,Ger-
many)accordingtothemanufacturer’sinstructions.RT-PCR
was then performed using the Access RT-PCR kit (Promega
Corporation, Madison, Wis, USA) according to the manu-
facturer’s directions, with 100ng of RNA being used for each
reaction. The primers used in the reaction were synthesized
according to standard methods and displayed in Table 1.T h e
PCR conditions were as follows: 45 minutes at 45◦C, 2 min-
utes at 94◦C followed by 30 cycles of 30 seconds at 94◦Cf o l -
lowed by 1 minute at 58◦C, and then 90 seconds at 68◦C. All
PCRs were performed in a reaction volume of 50μL.
2.9. Statisticalanalysis
Data are represented as mean ± SE and were analyzed with
the Prism 4.0 statistical program (GraphPad Software, San
Diego, Calif, USA). Comparisons between two experimen-
tal groups were performed with Student t test. Comparisons
among ≥ 3 experimental groups were performed with anal-
ysis of variance (ANOVA) followed by Dunnett’s adjustment
for multiple comparisons. Diﬀerences were considered sig-
niﬁcant if P<. 05. All experiments were performed on at
least three separate occasions unless otherwise speciﬁed.
3. RESULTS
3.1. TroglitazoneincreasesFcγ receptor-mediated
phagocytosisinratAMsbutnotPMs
Troglitazone is a thiazolidinedione no longer approved for
human use but still commonly used experimentally to ac-
tivate PPAR-γ. An earlier study demonstrated that doses
>10μM decreased Fcγ receptor-mediated phagocytosis in a
macrophage-like cell line, although this eﬀect was accom-
panied by apoptosis [22]. To study Fcγ receptor-mediated
phagocytosis in a more biologically relevant system, we em-
ployed lower, nonapoptotic inducing doses of this drug us-
ingprimaryAMs.Asshown(Figures1(a)and1(b)),troglita-
zone enhanced the ingestion of IgG-SRBCs by rat AMs, with
the eﬀect being both dose- and time-dependent. The peak4 PPAR Research
Table 1: Primer sequences used for RT-PCR.
Gene Primer
FcγRI Forward 5 -GAG CAG GGA AAG AAA GCA AAT TCC-3 
Reverse 5 -TTA AGA GTT GCA TGC CAT GGT CC-3  (232bp)
FcγRIIB Forward 5 -CCC AAG TCC AGC AGG TCT TTA CC-3 
Reverse 5 -TTC TGG CTT GCT TTT CCC AAT GCC-3  (277bp)
FcγRIII Forward 5 -GAT CCA GCA ACT ACA TCC TCC ATC-3 
Reverse 5 -GCC TTG AAC TGG TGA TCC TAA GTC-3  (333bp)
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Figure 1: Stimulation of Fcγ receptor-mediated phagocytosis by
troglitazone in rat macrophages. Rat alveolar macrophages (AMs)
were treated for 16 hours with troglitazone at the doses indicated by
(a) or with 5μM troglitazone for the times indicated by (b) prior to
the challenge with IgG-opsonized sheep red blood cells (SRBCs). In
(c), both AMs and peritoneal macrophages (PMs) were treated for
16 hours with 5μM troglitazone before phagocytosis was assessed,
as described in Section 2. ∗P<. 05 and ∗∗P<. 01 compared to un-
treated cells.
eﬀect occurred with a 16-hour incubation in the presence
of 5μM troglitazone; this exposure increased phagocytosis
to 199 ±12.4% of the untreated value (Figure 1(b)). At this
dose of troglitazone, apoptosis was not observed (data were
not shown).
Unlike AMs, PMs express little PPAR-γ [6]. We specu-
lated that the eﬀect of troglitazone would be more potent in
AMs than PMs, reﬂecting the diﬀerences in PPAR-γ expres-
sion.Indeed,weobservednoincreaseintheingestionofIgG-
SRBCs by rat PMs treated with troglitazone (Figure 1(c)).
3.2. TroglitazoneenhancesFcγ receptor-mediated
phagocytosisinmurineAMsbutnotPMs
To address the generalizability of our initial observation, we
repeated our experiments using murine macrophages and
ad i ﬀerent IgG-opsonized target, an IgG-coated polystyrene
bead. Figure 2 demonstrates that troglitazone enhanced Fcγ
receptor-mediated phagocytosis by AMs over the same con-
centration range observed for the rat, while no eﬀects were
seen in the PMs.
3.3. MultiplePPAR-γ ligandsenhanceFcγ
receptor-mediatedphagocytosisbyAMs
The above studies were limited by (a) the application of
a single PPAR-γ ligand with known/suspected PPAR-γ-
independent signaling properties [23] and (b) the use of
nonphysiological targets of IgG-opsonization. We therefore
tested the ability of rat AMs to ingest IgG-opsonized bac-
teria using the relevant Gram-negative pathogen K. pneu-
moniae. As demonstrated in Figure 3, troglitazone, rosiglita-
zone, and 15d-PGJ2 each increased phagocytosis of K. pneu-
moniae by ∼20%–25% when administered to the cells at a
10μMconcentration.Thus,distinctPPAR-γ ligandsenhance
the ingestion of IgG-opsonized pathogens by primary lung
macrophages.
3.4. PPAR-γ activationdoesnotmodulateFcγ receptor
expression
PPAR-γ ligands have been shown to increase the phagocyto-
sis of apoptotic cells by increasing the cell surface expression
of the CD36 receptor [5]. By analogy, we speculated that the
observed stimulation of Fcγ receptor-mediated phagocytosis
by PPAR-γ ligands might reﬂect increased expression of that
receptor. We therefore performed RT-PCR for the Fcγ recep-
t o r sIa n dI I Iu s i n gR N Ae x t r a c t e df r o mm o u s eA M st r e a t e d
for 16 hours with 5μM troglitazone. We also considered an
alternative possibility that PPAR-γ activation might suppress
the expression of the Fcγ IIB receptor, which is an inhibitory
Fcγ receptor. However, we did not detect signiﬁcant diﬀer-
ences in the expression of any of these three receptors by RT-
PCR (Figure 4), conﬁrming the ﬂow-cytometric results ob-
tained by Kasono et al. using J774.A1 macrophages [22].David M. Aronoﬀ et al. 5
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Figure 2: Stimulation of Fcγ receptor-mediated phagocytosis by troglitazone in mouse macrophages. Murine AMs (a) and (b) or PMs (c)
were treated for 16 hours with 5μM troglitazone before phagocytosis of IgG-opsonized beads was assessed, as described in Section 2.P a n e l
(b) is a representative light microscopy ﬁeld (400x magniﬁcation) demonstrating the eﬀect of troglitazone (5μM, bottom panel) compared
to vehicle (top panel). ∗P<. 05 compared to untreated cells.
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Figure 3: PPAR-γ ligands enhance phagocytosis of opsonized K.
pneumoniae. Rat AMs were pretreated for 16 hours with troglita-
zone, rosiglitazone, or 15d-PGJ2 (each at 10μM) prior to infection
with immune serum-opsonized K. pneumoniae at a multiple of in-
fection of 50 : 1. Phagocytosis was determined after 30 minutes, as
detailed in Section 2. ∗∗∗P<. 001 compared to untreated cells.
3.5. Troglitazoneenhancespost-Fcγ receptor
signalinginAMs
Because the expression of Fcγ receptors was not altered by
troglitazone, we postulated that PPAR-γ activation might be
enhancing the intracellular signaling network involved in the
internalization of IgG-opsonized targets. We therefore tested
FcγRI FcγRIIB FcγRIII
+ − + − + − Tro. 5 μM
232bp
333bp
Figure 4: Expression of mRNA for Fcγ r e c e p t o r si sn o ta ﬀected by
PPAR-γ ligands. Mouse AMs were plated and treated for 16 hours
with either 5μM troglitazone or DMSO vehicle. RNA was isolated,
ampliﬁed by RT-PCR, and subjected to electrophoresis. The ex-
pected sizes of cDNAs for Fcγ receptors I, IIB, and III, respectively,
are 232, 277, and 333bp.
the eﬀect of troglitazone (5μM for 16 hours) on the acti-
vation of proximal and distal signaling molecules involved
in Fcγ receptor-mediated phagocytosis [24]. As shown in
Figure 5, the proximal tyrosine kinase Syk becomes phos-
phorylated when cells are challenged with IgG-SRBCs; this
phosphorylation was signiﬁcantly enhanced by troglitazone.
The extracellular signal-regulated protein kinases (ERK)-1
and -2 (also known as p42/44 proteins) are also important
in IgG-mediated phagocytosis [24]. We found that 16-hour
administration of troglitazone to AMs stimulated activation
of ERK-1 and -2 over and above that triggered by IgG-SRBCs
alone. Analysis showed that only prior treatment with trogli-
tazone led to statistically signiﬁcant increases in the phos-
phorylation of Syk or ERK proteins in response to opsonized
SRBCs (Figure 5).
4. DISCUSSION
In this study, we demonstrate that activation of PPAR-γ en-
hances the phagocytosis of IgG-opsonized targets via the
Fcγ class of receptors in AMs. To our knowledge, this is
the ﬁrst study to demonstrate that PPAR-γ ligands increase6 PPAR Research
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Figure 5:TroglitazoneenhancesSykandERKactivationduringFcγ
receptor-mediated phagocytosis. Rat AMs were treated with 5μM
troglitazone for 16 hourspriorto challenge with IgG-opsonized SR-
BCs. Unopsonized SRBCs were used as negative controls. Cells were
lyzed after 7 minutes and subjected to Western immunoblot analy-
sis. Bands labeled p42 and p44 represent ERK-1 and -2. The phos-
phorylation of Syk was identiﬁed on the tyrosine residues 525 and
526. Representative blots from three independent experiments are
shown. Values represent the mean (± SE) of the ratio of phosphy-
orylated to total proteins determined by band densitometry from
multiple experiments (n = 3 − 4), expressed relative to untreated
cells. ∗P<. 05 compared to untreated cells.
Fcγ receptor-mediated phagocytosis. Notably, the eﬀects of
troglitazone that were seen in AMs were not observed in res-
ident PMs. This result accords with the earlier ﬁnding that
AMs express signiﬁcantly more PPAR-γ than PMs do [6].
We hypothesized that PPAR-γ activation might regulate
Fcγ receptor-mediated phagocytosis based on the nuclear re-
ceptor’s known ability to enhance phagocytosis mediated via
other receptors on the cell surface. For example, PPAR-γ ac-
tivation has been shown to increase expression of the cell
surface receptor CD36, which is involved in the recognition
andinternalizationofapoptoticcells,andtherebytoenhance
apoptotic cell uptake by macrophages [5]. The phagocytosis
of senescent neutrophils and unopsonized polystyrene beads
by pancreatic stellate cells was also enhanced by PPAR-γ-
activating agents [9]. This eﬀect was also shown to result
from increased expression of the cell-surface receptor CD36,
although the receptor(s) involved was not speciﬁcally char-
acterized.
Our studies were strengthened by the use of AMs and
PMs from both rats and mice and by the use of multi-
ple IgG-opsonized targets, including standard SRBCs and
live bacterial pathogens. However, our results appear to dif-
fer from the only other published study of PPAR-γ ac-
tivation and receptor-mediated phagocytosis [22]. Using
the macrophage-like cell line J774.A1, Kasono et al. found
that troglitazone, pioglitazone, and 15d-PGJ2 suppressed
phagocytosis of IgG-opsonized SRBCs without—as we also
found—altering Fcγ receptor expression. However, the au-
thors demonstrated that both troglitazone and pioglitazone
induced signiﬁcant apoptosis in these cells at the same con-
centrationsusedtosuppressphagocytosis(15d-PGJ2 wasnot
tested). It therefore seems likely that the inhibition by PPAR-
γ ligands of Fcγ receptor-mediated ingestion in J774.A1 cells
occurred primarily as a consequence of cell death through
apoptosis.Itisnotable,however,thatKusanoetal.foundthat
both the suppression of phagocytosis and the induction of
apoptosis occurred at doses of troglitazone >30μM, whereas
ad o s eo f1 0μM caused an increase in phagocytosis that did
not reach statistical signiﬁcance. We also observed inhibition
of phagocytosis and cell death in AMs at concentrations of
troglitazone >10μM (data were not shown).
Although we found qualitatively similar, stimulatory ef-
fects of troglitazone on Fcγ receptor-mediated phagocytosis
using three unique phagocytic targets (erythrocytes, beads,
and K. pneumoniae), the magnitude of troglitazone’s eﬀects
diﬀered with regards to the model examined. The reasons for
this are not entirely clear. The greatest eﬀect of troglitazone
was seen in assays using inert targets (IgG-SRBCs and IgG-
beads), as compared to the use of live, serum-opsonized bac-
teria. We speculate that as yet undeﬁned diﬀerences between
the interactions of macrophages with live bacteria versus in-
teractions with inert targets might underlie these variabili-
ties.
Azuma et al. demonstrated that the PPAR-γ ligand
15d-PGJ2 dose dependently inhibited the phagocytosis by
glycogen-elicited (activated) PMs from Wistar rats of unop-
sonized Escherichia coli [25] (lack of opsonization implied
that phagocytosis was not mediated by the Fcγ receptor).
However, since PPAR-γ expression is known to be markedly
upregulated in activated compared to resident PMs [7], the
disparity between these results and our failure to ﬁnd an ef-
fect of troglitazone on phagocytosis via the Fcγ receptor in
resident PMs is not surprising.
The ﬁnding of activation of phagocytosis in AMs, rather
than the inhibition that Azuma et al. observed in activated
PMs, may be attributed to diﬀerences in the two cell types
[26,27]. The alveolus is constantlyexposed to pathogens and
irritant particles drawn in with the inspired air, and the in-
citingofaninﬂammatoryresponsetoinhaledirritantsmight
impair the ability of the alveolar space to participate in the
essential function of gas exchange. Studies have shown that
PPAR-γ ligands inhibit AM inﬂammatory responses, includ-
ing the production of reactive oxygen species, and the ex-
pression of pro-inﬂammatory cytokines and inducible nitric
oxide synthase [5, 6]. Phagocytosis without accompanying
inﬂammatory activity, however, does not threaten alveolar
function. There is, thus, no conﬂict between downregulation
ofinﬂammatoryresponsesandsimultaneousupregulationof
phagocytosismediatedbyeitherCD36receptors[5,9]orFcγ
receptors (this study). This point is further supported by the
ﬁnding of Sutterwala et al. in bone marrow macrophages, in
whichthebindingofmaterialssuchasIgG-opsonizedSRBCs
to the Fcγ receptor promoted the production of the anti-
inﬂammatory cytokine interleukin-10 and the resultant in-
hibition of the pro-inﬂammatory cytokine interleukin-12’s
production [28].
Regulation of Fcγ receptor expression and activity is
complex. Granulocyte-macrophage colony stimulating fac-
tor is required both for constitutive expression in AMs andDavid M. Aronoﬀ et al. 7
for upregulation of receptor expression by interferon-γ [29].
Mancuso et al. found that leukotrienes B4 and C4,a sw e l l
as 5-hydroxyeicosatrienoic acid (5-HETE), stimulated AM
phagocytosis of K. pneumoniae [16] .As u b s e q u e n ts t u d y
showedthatthiseﬀectwasspeciﬁctobacteriaopsonizedwith
IgG and due to downstream activation of Fcγ receptor inter-
nalizationandtransportratherthantoincreasedreceptorex-
pression [17] .T h e s es a m el e u k o t r i e n e ss t i m u l a t eA Mb a c t e -
ricidalactivitybyactivatingNADPHoxidaseandstimulating
production of H2O2 [18], an eﬀect that in this case is oppo-
site to that of PPAR-γ ligands. Conversely, reﬂecting the fre-
quent antagonism between leukotrienes and prostaglandins,
prostaglandin E2 has been shown to inhibit Fcγ receptor-
mediated phagocytosis in AMs [13].
We found that, just as with leukotrienes, increased Fcγ
receptor-mediated phagocytosis induced by PPAR-γ ligands
did not result from increased receptor expression. While the
PPAR-γ ligands did not alter Fcγ receptor mRNA expres-
sion, these studies do not rule out the possibility that the
ligands altered phagocytosis by increasing the surface ex-
pression of these receptors. Regardless, we infer from our
data that PPAR-γ ligands prime cells for an enhanced activa-
tion of downstream eﬀectors involved with postbinding in-
ternalization and transport, such as Syk, ERK-1, and ERK-2.
While our data support a mechanism whereby PPAR-γ lig-
ands stimulate post-Fcγ receptor signaling (rather than re-
ceptor expression), our work does not deﬁnitively establish
the true role of these signaling pathways in this process.
Syk, which is a protein tyrosine kinase, has been shown
to be essential for the transport of internalized Fc receptors
to lysosomes [30]. Enhancement of Fcγ receptor-mediated
phagocytosis in AMs by LTB4 has also been shown to de-
pend on Syk activation [21]. Our study appears to be the
ﬁrst to demonstrate eﬀects of PPAR-γ ligands on Syk activity.
Eﬀects of PPAR-γ ligands on ERK-1/2 activation, however,
have previously been established. For example, inhibition of
growth and induction of apoptosis by 15d-PGJ2 in a neu-
roblastoma cell line was associated with ERK activation [31]
as was troglitazone-induced arrest of cell growth in lung ade-
nocarcinoma cells[32].Similar eﬀectsof troglitazone in lung
cancer cells were shown to be blocked by inhibition of either
PPAR-γ expression or ERK-1/2 activity [33]. In a mouse os-
teoblastic cell line, induction of apoptosis by ciglitazone was
accompanied by increased amounts of phosphorylated ERK,
with cell death being blocked by both PPAR-γ and ERK an-
tagonists [34].
It may be questioned whether the eﬀects we saw were
necessarily mediated via PPAR-γ, since it is known that
15d-PGJ2 and thiazolidinediones can act through PPAR-γ-
independent mechanisms [35, 36]. Although the evidence is
indirect, ﬁnding similar eﬀects with troglitazone, rosiglita-
zone, and 15d-PGJ2 argues for an eﬀect mediated through
their common receptor. This conclusion is further strength-
ened by the observation that such eﬀects were seen in AMs,
where PPAR-γ expression is abundant, but not in resident
PMs that express relatively little of this receptor.
In summary, we demonstrate here that PPAR-γ ligands
stimulate phagocytosis via the Fcγ receptor in AMs but not
in PMs. This eﬀect does not depend on increased expression
of the cell-surface receptor, but rather on downstream acti-
vation of Syk, ERK-1, and ERK-2. In AMs, PPAR-γ ligands
thus stimulate phagocytosis mediated by two quite diﬀerent
classes of cell-surface receptors and do so via quite diﬀerent
mechanisms.
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